ticularly harsh , which included high rates of often irreversible Parkinsonian symptoms such as tard
ive dyskinesia . With the advent of atypical antipsychotics ( also known as second generation antips
ychotics ) came a dopamine antagonist with a comparable response rate but a far different , though s
till extensive , side-effect profile that included a lower risk of Parkinsonian symptoms but a highe
r risk of cardiovascular disease . Atypical antipsychotics remain the first-line treatment for psych
osis associated with various psychiatric and neurological disorders including schizophrenia , bipola
r disorder , major depressive disorder , anxiety disorders , dementia , and some autism spectrum dis
orders . It is now known that dopamine is the primary neurotransmitter implicated in psychotic sympt
omology . Thus , blocking dopamine receptors ( namely , the dopamine D2 receptors ) and decreasing d
opaminergic activity continues to be an effective but highly unrefined pharmacologic goal of antipsy
